Center for Advanced Preclinical Research: Capabilities

Schema showing development of the GEM model

In Vivo Capabilities

  • GEM engineering
  • Characterization and validation of GEM models
  • GEM model re-tooling/refinement
  • Adaptation of GEM models to syngeneic allograft models
  • Surgical techniques for generation of murine orthotopic transplant model cohorts
  • Pharmacokinetics and biodistribution of therapeutics in animal models
  • Pharmacodynamics: evaluation of drug effect on intended target in tumor tissue
  • Evaluation of therapeutic candidates in efficacy studies
  • Cancer prevention studies in GEM models
  • Imaging modalities (MRI, PET/CT, ultrasound, and bioluminescence) 
  • Accurate real-time tumor volume measurements based on live imaging
  • Biomarkers/molecular signatures of treatment response:                                          
    • Immunohistochemical stains
    • Transcriptome
    • Metabolome
  • Generation of novel PDX models from patient tissue

In Vitro Capabilities

  • ES cell derivation
  • Primary tumor cell culture establishment
  • iPSC technologies
  • Cell viability assays
  • CRISPR and recombineering allele construction
  • Histopathological assessment
  • Quantitative molecular pathology
  • Evaluation of drug target inhibition
  • Establishment of primary tumor cell culture from GEM, GDA or PDX models
  • Evaluation of drug potency in primary tumor cells/specific target validation assays